A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies
Sarah P. Blagden(Churchill Hospital), T.R. Jeffry Evans(Leiden University Medical Center), Pavlina Spiliopoulou(Beatson West of Scotland Cancer Centre), Helen E.J. Tyrrell(Churchill Hospital), Chrissie Butcher(University of Oxford), Laura Spiers(Churchill Hospital), Cathy Qi(MRC Clinical Trials Unit at UCL), L. Griffiths(Churchill Hospital), Chat Gnanaranjan(London Cancer), Essam Ghazaly(Queen Mary University of London), Joanna Moschandreas(Nuffield Orthopaedic Centre), Victoria K. Woodcock(Churchill Hospital)
Cited by 2
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
|Journal of Clinical Oncology|2018|274
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222